Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 17/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 3/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 3/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.69 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.65 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.65 |
| ▸ | ARRB1 | P49407 | 6/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3243590 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SLC6A4SLC6A2 | |
| SCHEMBL3239924 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SLC6A4SLC6A2 | |
| SCHEMBL5509157 | 0.89 | OPRM1 (0.81) | OPRM1OPRD1OPRK1SLC6A4SLC6A2 | |
| SCHEMBL13292252 | 0.87 | OPRM1 (0.77) | OPRM1OPRD1OPRK1SLC6A4SLC6A2 | |
| SCHEMBL3230874 | 0.86 | OPRM1 (0.76) | OPRM1OPRD1OPRK1SLC6A4SLC6A2 | |
| SCHEMBL5510269 | 0.86 | OPRM1 (0.76) | OPRM1OPRD1OPRK1SLC6A4SLC6A2 | |
| SCHEMBL3240361 | 0.85 | OPRM1 (0.74) | OPRM1OPRD1OPRK1SLC6A4SLC6A2 | |
| SCHEMBL3241161 | 0.84 | OPRM1 (0.73) | OPRM1OPRD1OPRK1SLC6A4SLC6A2 | |
| SCHEMBL20399328 | 0.82 | OPRM1 (0.69) | OPRM1OPRD1OPRK1SLC6A4SLC6A2 | |
| SCHEMBL29613630 | 0.82 | OPRM1 (0.69) | OPRM1OPRD1OPRK1SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1748978-B1 | CARBOXAMIDO OPIOID COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-04 | — | — | EP | claimed |
| US-7244866-B2 | Carboxamido opioid compounds | JANSSEN PHARMACEUTICAL N.V. (BE) | 2007-07-17 | — | — | US | claimed |
| US-20050256203-A1 | Carboxamido opioid compounds | JANSSEN PHARMACEUTICAL N.V. (BE) | 2005-11-17 | — | — | US | claimed |
| EP-1748978-B1 | CARBOXAMIDO OPIOID COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-04 | — | — | EP | disclosed |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
| US-7745492-B2 | Carboxamido opioid compounds | JANSSEN PHARMACEUTICAL (BE) | 2010-06-29 | — | — | US | disclosed |
| US-7745492-B2 | Carboxamido opioid compounds | JANSSEN PHARMACEUTICAL (BE) | 2010-06-29 | — | — | US | disclosed |
| US-7745492-B2 | Carboxamido opioid compounds | JANSSEN PHARMACEUTICAL (BE) | 2010-06-29 | — | — | US | disclosed |
| US-20080280990-A1 | CARBOXAMIDO OPIOID COMPOUNDS | CARSON JOHN R | 2008-11-13 | — | — | US | disclosed |
| US-20080280990-A1 | CARBOXAMIDO OPIOID COMPOUNDS | CARSON JOHN R | 2008-11-13 | — | — | US | disclosed |
| US-20080280990-A1 | CARBOXAMIDO OPIOID COMPOUNDS | CARSON JOHN R | 2008-11-13 | — | — | US | disclosed |
| US-20070244194-A1 | CARBOXAMIDO OPIOID COMPOUNDS | CARSON JOHN R | 2007-10-18 | — | — | US | disclosed |
| US-20070244194-A1 | CARBOXAMIDO OPIOID COMPOUNDS | CARSON JOHN R | 2007-10-18 | — | — | US | disclosed |
| US-20070244194-A1 | CARBOXAMIDO OPIOID COMPOUNDS | CARSON JOHN R | 2007-10-18 | — | — | US | disclosed |
| US-7244866-B2 | Carboxamido opioid compounds | JANSSEN PHARMACEUTICAL N.V. (BE) | 2007-07-17 | — | — | US | disclosed |
| US-7244866-B2 | Carboxamido opioid compounds | JANSSEN PHARMACEUTICAL N.V. (BE) | 2007-07-17 | — | — | US | disclosed |
| US-7244866-B2 | Carboxamido opioid compounds | JANSSEN PHARMACEUTICAL N.V. (BE) | 2007-07-17 | — | — | US | disclosed |
| US-20050256203-A1 | Carboxamido opioid compounds | JANSSEN PHARMACEUTICAL N.V. (BE) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | OPRM1 3673/4885OPRD1 4771/4885OPRK1 3979/4885 |
| US-20070244194-A1 | CARBOXAMIDO OPIOID COMPOUNDS | OPRM1, OPRK1, OPRL1 | OPRM1 1/4885OPRD1 4/4885OPRK1 2/4885 |
| US-20080280990-A1 | CARBOXAMIDO OPIOID COMPOUNDS | OPRM1, OPRK1, OPRL1 | OPRM1 1/4885OPRD1 4/4885OPRK1 2/4885 |
| US-20050256203-A1 | Carboxamido opioid compounds | OPRM1, OPRK1, OPRL1 | OPRM1 1/4885OPRD1 4/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.